Evotec Advances Strategic Neuroscience Partnership With Bristol Myers Squibb, Earning $25M Milestone Payment
Evotec Advances Strategic Neuroscience Partnership With Bristol Myers Squibb, Earning $25M Milestone Payment
Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress further research
關鍵科學成就推進了聯合神經科學管道，並向Evotec支付了2500萬美元用於進一步研究
Evotec SE announced progress within the Company's strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programmes. Evotec receives a US$ 25 m payment to progress further research.
Evotec SE宣佈公司與百時美施貴寶的戰略合作伙伴關係取得進展，進一步加強了先進神經科學項目的聯合渠道。Evotec獲得了2500萬美元的補助金，用於推進進一步的研究。
Evotec and Bristol Myers Squibb entered their strategic neuroscience collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases where there remains a significant unmet medical need for therapies that slow down or reverse disease progression. The progress announced here leverages Evotec's PanOmics platform in conjunction with patient-derived disease models, which is one of the largest and most sophisticated platforms in the industry.
Evotec 和 Bristol Myers Squibb 於 2016 年 12 月開始了神經科學戰略合作，以確定各種神經退行性疾病的治療方法，在這些疾病中，減緩或逆轉疾病進展的療法仍有大量未得到滿足的醫療需求。此處公佈的進展利用了Evotec的Panomics平台和患者衍生的疾病模型，後者是業內最大、最複雜的平台之一。